Correspondence 0000930413-22-002114 from LAZARD FUNDS INC (CIK 0000874964)
LAZARD FUNDS INC (CIK 0000874964)
Date: Dec. 15, 2022 · CIK: 0000874964 · Accession: 0000930413-22-002114
AI Filing Summary & Sentiment
File numbers found in text: 811-06312
Letter
VIA EDGAR CORRESPONDENCE Division of Investment Management Washington, D.C. 20549 Re: The Lazard Funds, Inc. (the “Registrant”) SEC File Nos. 33-40682 and 811-06312 Post-Effective Amendment No. 146 to the Registration Statement on Form N-1A
Dear Ms. O’Neal:
This letter responds to the comment provided to me and Claire Hinshaw of Dechert LLP in a telephonic discussion on November 29, 2022 with respect to your review of Post-Effective Amendment No. 146 to the Registrant’s registration statement filed with the U.S. Securities and Exchange Commission (“SEC”) on October 13, 2022. Post-Effective Amendment No. 146 was filed pursuant to Rule 485(a) under the Securities Act of 1933 for the purpose of registering shares of the Lazard US Convertibles Portfolio (the “Portfolio”), a new series of the Registrant. We have reproduced your comment below, followed by the Registrant’s response. Capitalized terms have the meanings attributed to such terms in the registration statement.
1. Comment: Please confirm whether, in connection with the fee waiver and expense limitation arrangement in place between the Investment Manager and the Registrant on behalf of the Portfolio (the “Expense Limitation Agreement”), the Investment Manager retains a right to seek reimbursement from the Portfolio for amounts waived or reimbursed by the Investment Manager pursuant to the Expense Limitation Agreement. If the Investment Manager retains such a right, please disclose the terms and conditions of this right in footnotes to the fee table.
Response: The Expense Limitation Agreement contains no provision for recoupment of fee waivers or expense reimbursements, and the Investment Manager has advised us that it will not seek recoupment from the Portfolio for any fee waivers and expense reimbursements pursuant to the Expense Limitation Agreement.
* * *
We believe that the foregoing has been responsive to the Staff’s comment. Please call the undersigned at
(212) 649-8707 if you wish to discuss this correspondence further.
Very truly yours,
/s/ Robert Spiro
Show Raw Text
CORRESP
1
filename1.htm
1095 Avenue of the Americas
New York, NY 10036-6797
+1 212 698 3500 Main
+1 212 698 3599 Fax
www.dechert.com
ROBERT
SPIRO
robert.spiro@dechert.com
+1 212 649 8707 Direct
December 15, 2022
VIA EDGAR CORRESPONDENCE
Ms. Deborah O’Neal
U.S. Securities and Exchange Commission
Division of Investment Management
100 F Street, NE
Washington, D.C. 20549
Re: The Lazard Funds, Inc. (the “Registrant”)
SEC File Nos. 33-40682 and 811-06312
Post-Effective Amendment No. 146 to the Registration Statement on Form
N-1A
Dear Ms. O’Neal:
This letter responds to the comment provided
to me and Claire Hinshaw of Dechert LLP in a telephonic discussion on November 29, 2022 with respect to your review of Post-Effective
Amendment No. 146 to the Registrant’s registration statement filed with the U.S. Securities and Exchange Commission (“SEC”)
on October 13, 2022. Post-Effective Amendment No. 146 was filed pursuant to Rule 485(a) under the Securities Act of 1933 for the purpose
of registering shares of the Lazard US Convertibles Portfolio (the “Portfolio”), a new series of the Registrant. We have reproduced
your comment below, followed by the Registrant’s response. Capitalized terms have the meanings attributed to such terms in the registration
statement.
1. Comment: Please confirm whether, in connection with the fee waiver and expense limitation arrangement
in place between the Investment Manager and the Registrant on behalf of the Portfolio (the “Expense Limitation Agreement”),
the Investment Manager retains a right to seek reimbursement from the Portfolio for amounts waived or reimbursed by the Investment Manager
pursuant to the Expense Limitation Agreement. If the Investment Manager retains such a right, please disclose the terms and conditions
of this right in footnotes to the fee table.
Response: The Expense Limitation Agreement contains no provision for recoupment of fee waivers or expense reimbursements, and the
Investment Manager has advised us that it will not seek recoupment from the Portfolio for any fee waivers and expense reimbursements pursuant
to the Expense Limitation Agreement.
* * *
We believe that the foregoing has been
responsive to the Staff’s comment. Please call the undersigned at
(212) 649-8707 if you wish to discuss this correspondence further.
Very truly yours,
/s/ Robert Spiro
Robert Spiro